Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example ArtifactAssessment: Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)

Generated Narrative: ArtifactAssessment 179693

version: 6; Last updated: 2023-12-04 21:34:42+0000

Profile: CertaintyOfEvidence

Artifact URL: https://fevir.net/resources/ArtifactAssessment/179693

Artifact Description:

This example of a CertaintyOfEvidence Profile shows a recursive pattern of component elements with type/classifier paired values for different aspects of rating the certainty of evidence.

identifier: FEvIR Object Identifier/179693

title: Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)

artifact: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)

content

informationType: Rating

summary:

Low certainty due to inconsistency and risk of bias

type: Overall certainty

classifier: Low quality

component

informationType: Rating

type: Publication bias

classifier: no serious concern

component

informationType: Rating

summary:

There is a high degree of heterogeneity (I-squared = 73%). There is also inconsistency in findings between the fixed-effect and random-effects statistical models.

type: Inconsistency

classifier: serious concern

component

informationType: Rating

summary:

Although the random-effects analysis finds an estimate without statistical significance, this imprecision is explained by the inconsistency (heterogeneity) and thus not further downrated in certainty assessment.

type: Imprecision

classifier: no serious concern

component

informationType: Rating

type: Indirectness

classifier: no serious concern

component

informationType: Rating

type: Risk of bias

classifier: serious concern

Components

-InformationTypeSummaryTypeClassifier
*Rating

No blinding (no placebo control) in the largest trial

Lack of blindingpresent